Cocrystal Pharma, Inc. (COCP) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
Analysts estimate Earnings Per Share (EPS) of $-1.93 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.72 vs est $-1.93 (beat +10.9%). 2025: actual $-0.78 vs est $-0.80 (beat +1.9%). Analyst accuracy: 93%.
COCP Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Cocrystal Pharma, Inc. in the past 3 months
EPS Estimates — COCP
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.72
vs Est –$1.93
▲ 12.2% off
2025
Actual –$0.78
vs Est –$0.80
▲ 1.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — COCP
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
